CBD (Cannabidiol).

Cannabidiol dissolves readily in triglycerides and barely at all in water, so a lipid carrier is what makes an oral dose dispersible in the first place. Medium chain triglycerides are used because they stay liquid, resist oxidation better than most long chain oils and disperse quickly in the gut. This is formulation chemistry rather than a biological synergy.

Oral cannabidiol absorption depends on bile-driven micelle formation, so the amount of fat eaten with a dose changes how much enters circulation. Any long chain fat does this, and an omega-3 oil is a common co-ingredient in the same softgel. The effect is on absorption, not on activity at the target.

A double-blind randomised study in dogs gave cannabidiol together with krill oil and reported improvement in joint comfort and mobility measures. Because both were given together, the design cannot separate the contribution of either one. The phospholipid-bound fats in krill oil also act as a lipid vehicle for a lipophilic cannabinoid.

Melatonin acts on MT1 and MT2 receptors to shift circadian timing, a different mechanism from cannabidiol's activity at 5-HT1A and TRPV1. The two are routinely combined in night-time products, and reported drowsiness may stack. No trial isolates the pair, so the reasoning is mechanistic and the practical note is to expect additive sedation.

L-theanine raises alpha-band cortical activity and modulates glutamate signalling, while cannabidiol works through endocannabinoid tone and serotonergic 5-HT1A signalling. Because the targets do not overlap, the pair is a common daytime calm formula. Support is mechanism-level rather than a combination trial.

Piperine inhibits CYP3A4 and P-glycoprotein and slows glucuronidation, all of which reduce first-pass loss of co-administered lipophilic compounds. Applied to cannabidiol this is expected to raise exposure from the same nominal dose. That cuts both ways: the same inhibition applies to anything else being cleared through those enzymes, so the combination is a pharmacokinetic change to declare, not a free gain.

Curcumin inhibits several CYP isoforms and UGT enzymes in vitro, overlapping the routes that clear cannabidiol. Sharing one lipid base also means the two compete for the same micellar capacity during absorption. The direction of the net effect in people has not been measured, so this is a flagged interaction rather than a claimed benefit.

Hyperforin activates the pregnane X receptor, which upregulates CYP3A4 and P-glycoprotein. Cannabidiol is cleared substantially through CYP3A4, so co-administration is expected to lower its plasma exposure from the same dose. This is textbook induction pharmacology and worth a label flag rather than a pairing.

Cannabidiol inhibits CYP1A2 among other isoforms, and caffeine is cleared largely by CYP1A2, so co-use may slow caffeine turnover and extend its effect. The two also pull in opposite directions on alertness. People combining them should expect an altered caffeine time course rather than a simple sum of the two.

Cannabinoids in an oil base oxidise and degrade on exposure to light, heat and air. Mixed tocopherols are a standard chain-breaking antioxidant added to protect the vehicle and, with it, cannabinoid content over shelf life. The benefit is to the product, not to the person.

Lecithin phospholipids form the interface in nanoemulsions and liposomal dispersions, letting a fat-soluble cannabinoid disperse into a beverage or a fast-dissolve format. The dispersion changes how quickly the dose disperses, which is a formulation property. Whether it changes clinical response has not been settled.

Magnesium is a cofactor in hundreds of enzymatic reactions and contributes to normal neuromuscular signalling, which has nothing in common with cannabinoid receptor pharmacology. The glycinate form also delivers glycine, itself an inhibitory transmitter. The pairing is a formulation convention supported by non-overlapping mechanisms rather than by a combination trial.